Improved glycemic control in mice lacking Sglt1 and Sglt2.
about
Stimulation of incretin secreting cellsNovel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansImpact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Novel Agents for the Treatment of Type 2 Diabetes.Amoxicillin and amoxicillin/clavulanate reduce ethanol intake and increase GLT-1 expression as well as AKT phosphorylation in mesocorticolimbic regions.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusSGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateSotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesInhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapySGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Molecular mechanisms of incretin hormone secretion.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Sotagliflozin as a potential treatment for type 2 diabetes mellitus.Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Intestinal SGLT1 in metabolic health and disease.Fingerprints of hSGLT5 sugar and cation selectivity.Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humansStudy design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice.A more tubulocentric view of diabetic kidney disease.Efficacy and safety of sotagliflozin in treating diabetes type 1.Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.Intestinal absorption of glucose in mice as determined by positron emission tomography.
P2860
Q26765259-A52D9761-B90F-4CD2-B368-9A98F8BC009BQ33356608-A4510540-F11B-4782-8F74-41465D78AB4AQ33625568-AACD577D-8FD0-4B1A-A04A-4D6AFEF0DFE4Q35137042-CC00198D-2B72-46D0-BA72-CC49D5CDC2BFQ35392355-4066B469-2462-4240-A527-30846BF24588Q35664940-C101881D-EE08-4D28-9DFA-969DCD34E0D0Q35672654-C0A01EFF-454A-450D-9B88-7978713C6AD3Q35910421-283C3DFD-137D-4D5C-874F-4C0B51BD4DCFQ36037560-497E6F20-D8C9-44B1-B40F-74D18B595FE1Q36237217-90EC76F7-878E-4984-A1A1-943D331858CAQ36345951-3EF2D151-1D7D-4158-8975-F1EECC16EB09Q36372598-C2721679-9434-41CF-B2A6-8E714054A92EQ36435496-DC0A347E-2B62-4802-BDB8-18C01229BB72Q36798680-85CEE646-756A-48A6-91CA-E0BFED2E6AABQ37042588-6892F12D-3A8D-4CC1-89CC-3752C032A7D8Q37193454-FEEFF694-8293-46A6-96E4-8DE11AD572CDQ37206282-3D4CF0C8-56B6-4CC9-AA8F-DCE897B8DE76Q37461695-E10F7158-E262-4289-954C-97320853E309Q37575455-26881160-F811-4EF1-B22D-1FD61B51AFB9Q37575461-2C60126A-B8B5-4AEF-9E72-457E6FC04B23Q38104746-2BE70AE9-7E43-4605-AE43-5B07C426DE01Q38130748-FA4CC873-9C7D-4035-8872-270C418490FAQ38137525-636FD3E1-E4AA-4BA1-8DE7-6F7852629DD7Q38330456-56FEEA57-A482-48CB-B880-8AC8F3BDDDFEQ38358921-38A6B4DB-54B9-4863-99E3-A1FE10A4DC79Q38537119-848E2A5D-55B4-45E8-A256-80ED99331A95Q38628037-DF3A888B-F0AD-4304-A015-7B30EECC38EAQ38638523-0C86A8E2-8F98-484D-B4DE-FB240F504985Q38775305-97C43B51-2768-4AC7-8B16-C2E1BA9BAB37Q38783130-88331CA0-0C31-4920-B063-D3BF4DB5BA02Q38787917-3325B645-593B-4C5B-807D-9BEAA1B8307EQ39020680-E4A44047-4235-4A0B-BF39-6F658D26AC4DQ39398592-FBF30A84-0E7B-4733-B954-98D824C7665DQ41649918-1A6EAE04-3FBA-40DE-8C64-EF178F63A670Q44757675-1C003E3D-8611-48AD-B5D4-212C69B8D91FQ46132953-CA999025-8141-494E-8B87-C7A897764F00Q47108081-60A66065-AD86-4FBE-AEAD-B91D686FC553Q50047534-13895E0F-0A3B-4DB3-966C-1F117A871510Q51304272-8ACEBA02-AC8D-46CE-BF48-2C70C5096483Q55514768-0211E800-FC65-43AB-913E-2F6B51569F08
P2860
Improved glycemic control in mice lacking Sglt1 and Sglt2.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@en
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@nl
type
label
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@en
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@nl
prefLabel
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@en
Improved glycemic control in mice lacking Sglt1 and Sglt2.
@nl
P2093
P2860
P1476
Improved glycemic control in mice lacking Sglt1 and Sglt2
@en
P2093
Angela Harris
Arthur T Sands
Brian Zambrowicz
Christopher M DaCosta
David R Powell
Deon Doree
Faika Mseeh
Jennifer Greer
Kenneth A Platt
P2860
P304
P356
10.1152/AJPENDO.00439.2012
P50
P577
2012-11-13T00:00:00Z